Adaptimmune Therapeutics (NASDAQ:ADAP) Share Price Crosses Below 50-Day Moving Average – What’s Next?

Adaptimmune Therapeutics plc (NASDAQ:ADAP)’s share price passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $0.60 and traded as low as $0.57. Adaptimmune Therapeutics shares last traded at $0.60, with a volume of 613,593 shares.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. StockNews.com cut Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Guggenheim lowered their target price on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Mizuho lowered their target price on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a research report on Wednesday, November 27th. Finally, HC Wainwright lowered their target price on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Adaptimmune Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $2.79.

Adaptimmune Therapeutics Trading Down 3.1 %

The company has a market capitalization of $153.79 million, a price-to-earnings ratio of -2.73 and a beta of 2.42. The firm has a 50-day moving average price of $0.60 and a 200-day moving average price of $0.83. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Several hedge funds have recently modified their holdings of ADAP. Fullcircle Wealth LLC acquired a new position in shares of Adaptimmune Therapeutics during the 3rd quarter valued at $33,000. Vontobel Holding Ltd. increased its position in shares of Adaptimmune Therapeutics by 230.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 30,000 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Adaptimmune Therapeutics during the 3rd quarter valued at $95,000. Virtu Financial LLC increased its position in shares of Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 21,769 shares during the period. Finally, Jane Street Group LLC increased its position in shares of Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 98,581 shares during the period. 31.37% of the stock is currently owned by institutional investors and hedge funds.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.